AGEN — AGENUS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1098972 ·
Last close
$7.50
Market Cap
$312.32M
52W High
$8.70
52W Low
$2.85
ADV30
7,652,293
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 33,736,000 | 21,914,000 | 15,054,000 | 39,226,000 | 186,456,000 | 34,996,000 | 414,439,000 |
| Dec 2025 | 34,204,000 | 26,693,000 | 14,398,000 | -10,578,000 | 226,798,000 | 2,998,000 | 504,659,000 |
| Sep 2025 | 30,235,000 | 5,997,000 | -4,863,000 | 63,914,000 | 233,891,000 | 3,458,000 | 514,759,000 |
| Jun 2025 | 25,691,000 | -1,262,000 | -16,780,000 | -27,955,000 | 185,221,000 | 9,534,000 | 521,529,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,527,000
Investing CF
$70,089,000
Financing CF
$32,006,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
$-92,000
EPS Diluted TTM
$0.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,182,765,000
Inventory
—
Receivables
$7,010,000
ST Investments
—
EBIT TTM
$52,190,000
Pretax Income TTM
$-3,083,000
Interest Exp TTM
$55,273,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$123,866,000
EBITDA
$15,188,000
Free Cash Flow
$-53,024,876
Enterprise Value
$311,634,240
Total Cash
$34,996,000
Total Debt
$41,074,000
Shares Out
41,642,431
Trailing EPS
$2.05
Book Value
$-5.74
ROE
—
ROA
2.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 114,196,000 | -20,556,000 | 115,000 | 226,798,000 | 504,659,000 | — | -77,195,000 |
| Dec 2024 | 103,463,000 | -124,429,000 | -227,212,000 | 226,271,000 | 532,695,000 | — | -158,315,000 |
| Dec 2023 | 156,314,000 | -160,105,000 | -245,761,000 | 313,913,000 | 462,295,000 | — | -224,202,000 |
| Dec 2022 | 98,024,000 | -180,242,000 | -220,074,000 | 413,556,000 | 468,458,000 | — | -175,373,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.06
Max Pain — expiry 2026-08-21
max pain strike: $7.00 · spot: $7.50 · call oi: 16,645 · put oi: 7,808
Expected Move to 2026-08-21:
±$1.80
(24.00%) —
implied range
$5.70 –
$9.30
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PROK | PROKIDNEY CORP. | $316.01M | $1.54 | — |
| LXEO | Lexeo Therapeutics, Inc. | $324.29M | $4.13 | — |
| NMRA | Neumora Therapeutics, Inc. | $298.31M | $1.61 | — |
| PALI | PALISADE BIO, INC. | $329.80M | $1.90 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $332.43M | $9.57 | — |
News headlines (Yahoo Finance, 1h cache)
Agenus (AGEN) Earnings Expected to Grow: Should You Buy?
2026-07-30 14:00 · Yahoo
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
2026-07-28 20:30 · Yahoo
Do Options Traders Know Something About Agenus Stock We Don't?
2026-07-23 17:11 · Yahoo
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
2026-07-17 20:11 · Yahoo
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
2026-07-17 14:28 · Yahoo
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
2026-07-14 15:57 · Yahoo
Agenus stock doubles as biotech narrows Phase 3 bet
2026-07-14 14:17 · Yahoo
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
2026-07-14 12:15 · Yahoo
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
2026-07-14 10:15 · Yahoo
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment
2026-07-13 18:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.